Breaking News Instant updates and real-time market news.

AMGN

Amgen

$207.30

2.25 (1.10%)

05:26
09/25/18
09/25
05:26
09/25/18
05:26

Amgen announces approval for Blincyto in Japan

Amgen announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for Blincyto for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia. Blincyto was developed in Japan by Amgen Astellas BioPharma K.K., or AABP, a joint venture between Amgen and Astellas Pharma Inc., a pharmaceutical company headquartered in Tokyo. Blincyto is the first-and-only bispecific T cell engager immunotherapy construct approved globally. It is also the first approved immunotherapy from Amgen's BiTE platform, an innovative approach that helps the body's immune system target cancer cells.

  • 26

    Sep

  • 17

    Oct

  • 22

    Oct

  • 09

    Nov

AMGN Amgen
$207.30

2.25 (1.10%)

09/05/18
JEFF
09/05/18
NO CHANGE
Target $220
JEFF
Buy
Amgen shares should rally as biosimilar fears pass, says Jefferies
After meeting with Amgen's biosimilar head to discuss the current landscape, Jefferies analyst Michael Yee continues to believe Amgen shares should climb as the company manages numbers in the face of competition, especially as "fear" of initial competition and worst case scenarios pass. Amgen's Scott Foraker considers biosimilar competition as manageable against Neulasta, while also an attractive and profitable long-term business as Amgen has 10 of their own over next five years, Yee tells investors in a research note. The analyst keeps a Buy rating on Amgen with a $220 price target.
09/11/18
WELS
09/11/18
NO CHANGE
WELS
Amgen's AMG420 risk overstated, says Wells Fargo
Wells Fargo analyst Jim Birchenough believes shares of Bluebird Bio (BLUE) have been under pressure on concerns regarding potential competitive risk to BCMA CAR T therapeutic bb2121 from Amgen's (AMGN) bispecific T cell engager AMG420. The analyst highlights that AMGN420 is a continuous IV infusion and in his opinion not a viable competitor to a single bb2121 cell therapy dose, particularly given long-term durability of response with bb2121. Further, he notes that Amgen's approved first generation CD19 bispecific engager, BLINCYTO, is dosed as a continuous IV for 4 weeks out of every 6 and achieved only $175M in sales in 2017 following 2015 approval. He does not view this dose schedule for first generation bispecific T cell engagers as commercially viable in a more chronic cancer. Additionally, the analyst points out that Affimed (AFMD) also has a preclinical BCMA engager AFM26, established proof-of-concept data for CD30 bispecific AFM13, and upcoming proof-of-concept data for CD19 bispecific AFM11.
09/17/18
FBCO
09/17/18
NO CHANGE
Target $26
FBCO
Neutral
Teva price target raised to $26 from $23 at Credit Suisse
Credit Suisse analyst Vamil Divan reiterated a Neutral rating on Teva Pharmaceutical (TEVA) and raised his price target to $26 after the company said it received FDA approval for Ajovy, a key pipeline drug for migraine prevention and approval of a quarterly dosing for the drug, providing an important point of differentiation relative to competitors from Eli Lilly (LLY) and Amgen (AMGN)/Novartis (NVS). In a research note to investors, Divan says Friday's approval provides Teva with an important potential growth driver as it looks to overcome the challenges it faces with U.S. generics, Copaxone and its large debt load, and expects a "strong" positive reaction in the stock. Divan says he will look to see how Teva commercializes Ajovy in the coming months before becoming more constructive on the stock's longer-term outlook.
09/19/18
LEER
09/19/18
NO CHANGE
LEER
Outperform
Leerink 'incrementally positive on state of generics industry following meetings
Leerink analyst Ami Fadia tells investors in a research note that she is "incrementally positive" on the state of the generics industry following investor meetings with the management teams from Outperform-rated Amneal (AMRX), Pfenex and Teligent. Fadia says a key takeaway from the teams is that the FDA is placing additional emphasis on reviewing and approving complex generics, and while there is starting to be more first-to-market approvals, there are also more approvals for the second and third generic entrants. Additionally, Fadia says the complex generic opportunity will likely be characterized by a slower-than-typical launch ramp, but also extended duration of meaningful financial contribution due to less overall competitors vs that for oral-solid generics and that while companies still regard biosimilar assets as attractive, the low penetration for biosimilar Remicade in the U.S., Mylan's (MYL) slow start with Fulphila and extended litigation timelines mean management teams looking to participate in this space are taking a more prudent approach and minimizing their upfront investment.

TODAY'S FREE FLY STORIES

FB

Facebook

$180.89

(0.00%)

, SNE

Sony

$48.36

(0.00%)

09:41
05/24/19
05/24
09:41
05/24/19
09:41
Periodicals
Snapchat wants to let users add music to posts, WSJ says »

Anne Steele and Georgia…

FB

Facebook

$180.89

(0.00%)

SNE

Sony

$48.36

(0.00%)

VIVHY

Vivendi

$0.00

(0.00%)

SNAP

Snap

$11.13

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 30

    May

  • 03

    Jun

  • 03

    Jun

  • 10

    Jun

AMZN

Amazon.com

$1,815.30

(0.00%)

, BABA

Alibaba

$156.13

(0.00%)

09:41
05/24/19
05/24
09:41
05/24/19
09:41
On The Fly
Piper sees Amazon on way to $3,000 in today's top analyst call »

Check out today's top…

AMZN

Amazon.com

$1,815.30

(0.00%)

BABA

Alibaba

$156.13

(0.00%)

STZ

Constellation Brands

$206.21

(0.00%)

APHA

Aphria

$6.40

(0.00%)

CGC

Canopy Growth

$44.58

(0.00%)

ACB

Aurora Cannabis

$8.26

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

  • 06

    Jun

  • 18

    Jun

  • 25

    Jun

SPLK

Splunk

$128.68

(0.00%)

, ADSK

Autodesk

$169.64

(0.00%)

09:40
05/24/19
05/24
09:40
05/24/19
09:40
Options
Unusually active option classes on open May 24th »

Unusual total active…

SPLK

Splunk

$128.68

(0.00%)

ADSK

Autodesk

$169.64

(0.00%)

MDT

Medtronic

$91.72

(0.00%)

IQ

iQIYI

$18.82

(0.00%)

UBER

Uber

$40.46

(0.00%)

ORCL

Oracle

$53.07

(0.00%)

SNAP

Snap

$11.13

(0.00%)

VALE

Vale

$11.78

(0.00%)

TGT

Target

$79.40

(0.00%)

CVX

Chevron

$117.91

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 29

    May

  • 30

    May

  • 03

    Jun

  • 10

    Jun

  • 12

    Jun

  • 12

    Jun

  • 13

    Jun

  • 09

    Jul

SHLX

Shell Midstream

$21.32

-0.33 (-1.52%)

09:35
05/24/19
05/24
09:35
05/24/19
09:35
Hot Stocks
Shell Midstream: Systems owned by Proteus, Endymion boost Appomattox volumes »

Shell Midstream Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENTA

Enanta

$92.13

-1.31 (-1.40%)

09:33
05/24/19
05/24
09:33
05/24/19
09:33
Initiation
Enanta initiated  »

Enanta initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIPS

Vipshop

$7.50

-0.25 (-3.23%)

09:33
05/24/19
05/24
09:33
05/24/19
09:33
Upgrade
Vipshop rating change  »

Vipshop upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRYS

Krystal Biotech

$32.05

-0.27 (-0.84%)

09:31
05/24/19
05/24
09:31
05/24/19
09:31
Recommendations
Krystal Biotech analyst commentary  »

Krystal Biotech price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

ARMK

Aramark

$31.18

-0.63 (-1.98%)

09:30
05/24/19
05/24
09:30
05/24/19
09:30
Conference/Events
Aramark management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

SINA

Sina

$42.56

-4.94 (-10.40%)

, WB

Weibo

$45.40

-5.85 (-11.41%)

09:29
05/24/19
05/24
09:29
05/24/19
09:29
Recommendations
Sina, Weibo analyst commentary  »

Sina, Weibo price targets…

SINA

Sina

$42.56

-4.94 (-10.40%)

WB

Weibo

$45.40

-5.85 (-11.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPRO

GoPro

$7.15

-0.1 (-1.38%)

09:28
05/24/19
05/24
09:28
05/24/19
09:28
Hot Stocks
GoPro expands Trade-Up program to countries in European Union »

GoPro announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

RVLT

Revolution Lighting

$0.18

0.004 (2.34%)

09:28
05/24/19
05/24
09:28
05/24/19
09:28
Hot Stocks
Revolution Lighting receives stay of delisting from Nasdaq »

Revolution Lighting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSAT

ViaSat

$87.89

-1.63 (-1.82%)

09:26
05/24/19
05/24
09:26
05/24/19
09:26
Recommendations
ViaSat analyst commentary  »

ViaSat price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$52.85

-1.355 (-2.50%)

09:26
05/24/19
05/24
09:26
05/24/19
09:26
Hot Stocks
Foot Locker still expects to open over a dozen Power stores in 2019 »

Says on track to open 15…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 09

    Jul

KTB

Kontoor Brands

$38.51

0.82 (2.18%)

09:25
05/24/19
05/24
09:25
05/24/19
09:25
Initiation
Kontoor Brands initiated  »

Kontoor Brands initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:25
05/24/19
05/24
09:25
05/24/19
09:25
General news
The April U.S. durables report »

The April U.S. durables…

09:25
05/24/19
05/24
09:25
05/24/19
09:25
Conference/Events
Helsinki Commission and House Financial Services Committee holds briefing »

The Helsinki Commission…

ANTM

Anthem

$277.80

-5.16 (-1.82%)

09:25
05/24/19
05/24
09:25
05/24/19
09:25
Conference/Events
Anthem participates in a conference call with JPMorgan »

Managed Care/Facilities…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 29

    May

QGEN

Qiagen

$38.48

-0.235 (-0.61%)

09:25
05/24/19
05/24
09:25
05/24/19
09:25
Conference/Events
Qiagen participates in a conference call with JPMorgan »

Life Science &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 20

    Jun

  • 06

    Aug

EVOP

EVO Payments

$27.74

-0.75 (-2.63%)

09:24
05/24/19
05/24
09:24
05/24/19
09:24
Initiation
EVO Payments initiated  »

EVO Payments initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

  • 11

    Jun

TSS

TSYS

$99.61

-1.62 (-1.60%)

, GPN

Global Payments

$147.97

-2.64 (-1.75%)

09:24
05/24/19
05/24
09:24
05/24/19
09:24
Hot Stocks
Breaking Hot Stocks news story on TSYS, Global Payments »

TSYS jumps 7% to $107.00…

TSS

TSYS

$99.61

-1.62 (-1.60%)

GPN

Global Payments

$147.97

-2.64 (-1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

  • 05

    Jun

  • 13

    Nov

CPRT

Copart

$69.99

5 (7.69%)

09:21
05/24/19
05/24
09:21
05/24/19
09:21
Recommendations
Copart analyst commentary  »

Copart price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
05/24/19
05/24
09:18
05/24/19
09:18
Options
Overnight activity included 434 trades in SPX and 55 trades in VIX »

434 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$52.85

-1.355 (-2.50%)

09:17
05/24/19
05/24
09:17
05/24/19
09:17
Hot Stocks
Foot Locker sees low-to-mid single digit comp gain in Q2 »

Says inventory remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 09

    Jul

FSV

FirstService

$93.59

7.5 (8.71%)

09:16
05/24/19
05/24
09:16
05/24/19
09:16
Recommendations
FirstService analyst commentary  »

FirstService price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

MCK

McKesson

$129.11

-0.48 (-0.37%)

09:15
05/24/19
05/24
09:15
05/24/19
09:15
Conference/Events
McKesson participates in a conference call with JPMorgan »

Healthcare Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.